Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8881555 | 0.76 | POLB (0.40) | CA1CA9POLBMAPT | |
| SCHEMBL25269756 | 0.74 | PLA2G7 (0.32) | — | |
| SCHEMBL959235 | 0.71 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL16322256 | 0.71 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL16321921 | 0.70 | POLB (0.33) | POLBCYP19A1 | |
| SCHEMBL4329065 | 0.70 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL7620452 | 0.68 | POLB (0.39) | POLBALDH1A1CYP3A4CYP19A1 | |
| SCHEMBL450333 | 0.67 | — | — | |
| SCHEMBL12697758 | 0.67 | CES2 (0.33) | ALDH1A1CYP3A4MAPTCYP19A1 | |
| SCHEMBL125003 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295068-A1 | NOVEL CYCLOALKENONE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-4194435-A1 | NOVEL CYCLOALKENONE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-06-14 | — | — | EP | disclosed |
| CN-116096361-A | Novel cyclic enone compound or salt thereof | 大鹏药品工业株式会社 | 2023-05-09 | — | — | CN | disclosed |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-8299296-B2 | Spiro compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299296-B2 | Spiro compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2202216-B1 | SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170908-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | CA1 2819/4885CA9 285/4885POLB 4000/4885 |
| US-20150299090-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | CA1 2819/4885CA9 285/4885POLB 4000/4885 |
| US-20130109710-A1 | SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, PKD2 | CA1 2819/4885CA9 285/4885POLB 4000/4885 |
| US-20230295068-A1 | NOVEL CYCLOALKENONE COMPOUND OR SALT THEREOF | BDNF, SMN1; SMN2, ELAVL1 | CA1 3528/4885CA9 3304/4885POLB 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.